S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:VTYX

Ventyx Biosciences (VTYX) Stock Price, News & Analysis

$5.50
-0.30 (-5.17%)
(As of 03/28/2024 ET)
Today's Range
$5.43
$5.95
50-Day Range
$1.90
$10.13
52-Week Range
$1.87
$40.58
Volume
2.20 million shs
Average Volume
4.43 million shs
Market Capitalization
$325.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.75

Ventyx Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
295.5% Upside
$21.75 Price Target
Short Interest
Bearish
20.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.06mentions of Ventyx Biosciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.55) to ($2.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.48 out of 5 stars

Medical Sector

500th out of 938 stocks

Pharmaceutical Preparations Industry

230th out of 425 stocks

VTYX stock logo

About Ventyx Biosciences Stock (NASDAQ:VTYX)

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

VTYX Stock Price History

VTYX Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
VTYX Apr 2024 17.500 call
VTYX Apr 2024 10.000 put
See More Headlines
Receive VTYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VTYX
Fax
N/A
Employees
79
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.75
High Stock Price Target
$62.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+274.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-192,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.13 per share

Miscellaneous

Free Float
44,800,000
Market Cap
$343.95 million
Optionable
Optionable
Beta
0.36
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Sheila K. Gujrathi M.D. (Age 54)
    Executive Chairperson
    Comp: $125k
  • Dr. Raju S. Mohan Ph.D. (Age 67)
    Founder, CEO, President & Director
    Comp: $989.99k
  • Dr. John M. Nuss Ph.D. (Age 65)
    Chief Scientific Officer
    Comp: $656.99k
  • Dr. Martin Douglas Auster M.D. (Age 49)
    Chief Financial Officer
  • Mr. Christopher W. Krueger J.D. (Age 56)
    MBA, Chief Business Officer
    Comp: $568.14k

VTYX Stock Analysis - Frequently Asked Questions

Should I buy or sell Ventyx Biosciences stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VTYX shares.
View VTYX analyst ratings
or view top-rated stocks.

What is Ventyx Biosciences' stock price target for 2024?

9 brokers have issued 12 month target prices for Ventyx Biosciences' shares. Their VTYX share price targets range from $5.00 to $62.00. On average, they predict the company's share price to reach $21.75 in the next twelve months. This suggests a possible upside of 295.5% from the stock's current price.
View analysts price targets for VTYX
or view top-rated stocks among Wall Street analysts.

How have VTYX shares performed in 2024?

Ventyx Biosciences' stock was trading at $2.47 at the beginning of the year. Since then, VTYX stock has increased by 122.7% and is now trading at $5.50.
View the best growth stocks for 2024 here
.

When is Ventyx Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VTYX earnings forecast
.

How were Ventyx Biosciences' earnings last quarter?

Ventyx Biosciences, Inc. (NASDAQ:VTYX) issued its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.79) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.08. During the same period in the prior year, the firm earned ($0.62) EPS.

When did Ventyx Biosciences IPO?

Ventyx Biosciences (VTYX) raised $152 million in an IPO on Thursday, October 21st 2021. The company issued 9,472,656 shares at $15.00-$17.00 per share.

Who are Ventyx Biosciences' major shareholders?

Ventyx Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.34%), Vanguard Group Inc. (6.32%), Capital International Investors (3.99%), Goldman Sachs Group Inc. (2.31%), Goldman Sachs Group Inc. (2.30%) and Opaleye Management Inc. (1.93%). Insiders that own company stock include Christopher W Krueger, Global Strategic Fund I Venbio, John Nuss, Martin Auster, Nsv Partners Iii Lp, Raju Mohan, Sheila Gujrathi, Somu Subramaniam, William J Sandborn and William Richard White.
View institutional ownership trends
.

How do I buy shares of Ventyx Biosciences?

Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VTYX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners